A Phase I/II proof-of-concept clinical trial to investigate topical product candidate SNA-125 in the treatment of atopic dermatitis

Trial Profile

A Phase I/II proof-of-concept clinical trial to investigate topical product candidate SNA-125 in the treatment of atopic dermatitis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs SNA 125 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Sienna Biopharmaceuticals
  • Most Recent Events

    • 12 Mar 2018 According to Sienna Biopharmaceuticals media release, the first patient has been dosed in this trial.
    • 12 Mar 2018 According to Sienna Biopharmaceuticals media release, the company expects to report the results in the fourth quarter of 2018.
    • 12 Mar 2018 Status changed from planning to recruiting, according to Sienna Biopharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top